image
SOCIETIES:
mental health, psychiatry and mental health, journals on mental health, mental health journals, journals mental health
journals for mental health, best journals for mental health, mental health journals uk, journals on psychiatry
JOURNAL COVER:
journals of psychiatry, psychiatry journals, asean, journal
Google Scholar citation report
Citations : 934

ASEAN Journal of Psychiatry received 934 citations as per google scholar report

ASEAN Journal of Psychiatry peer review process verified at publons
IMPACT FACTOR:
Journal Name ASEAN Journal of Psychiatry (MyCite Report)  
Total Publications 32
Total Citations 16
Total Non-self Citations 12
Yearly Impact Factor 0.053
5-Year Impact Factor 0.104
Immediacy Index 0.000
Cited Half-life 2.7
H-index 3
Quartile
Social Sciences Medical & Health Sciences
Q3 Q2

Abstract

ESCITALOPRAM AND MIRTAZAPINE FOR THE TREATMENT OF DEPRESSION IN HIV PATIENTS: A RANDOMIZED CONTROLLED OPEN LABEL TRIAL

Author(s): Shanti Patel, Sanjay Kukreja, Umesh Atram, Avinash De Sousa, Nilesh Shah, Sameer Yadav, Sushma Sonavane

Objective: The objective of this study was to compare the safety and efficacy of mirtazapine and escitalopram in HIV patients for the treatment of depression. Methods: In this trial, 70 adult HIV patients with major depression were randomized and assigned to receive 8 weeks of daily open label mirtazapine (5-30 mg) or escitalopram (7.5-20 mg). The primary outcome variables were endpoint response in Hamilton Rating Scale for Depression (HAM-D) score and change of HAM-D score from baseline to endpoint. Patients having improvement of > 50% on the HAM-D total scores during treatment were considered to have responded. A final 17-item HAM-D total score of 8 or less defined remission. Results: The response rate was 91.4 % (32/35) in Mirtazapine group and 85.7 % (30/35) in Escitalopram group (p= 0.71). The remission rate was more in escitalopram group (48.6 %, 17/35) compared to Mirtazapine group (34.3 %, 12/35); however it was not statistically significant (Chi square (1, N = 70) = 2.1, p = 0.22). After controlling for baseline score, the median HAMD score at 8 weeks was significantly lower in the Mirtazapine group (Median (Mdn)=4, Interquartile range (IQR)= 11) compared to Escitalopram group (Mdn=13, IQR= 12) (p < 0.001). The number of adverse events reported was more in Escitalopram group (110) than Mirtazapine group (85); however this was not statistically significant (p= 0.34). Conclusions: Both these drugs are useful in the management of depression in HIV patients and need further study.


PDF

INDEXATION OF THE JOURNAL
Global Tech Summit
Get the App